Clinical Trials in Le Mans, France
2 recruiting
Showing 1–20 of 36 trials
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals500 enrolled49 locationsNCT05363319
Recruiting
Phase 2
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Pleural Mesotheliomas
Intergroupe Francophone de Cancerologie Thoracique38 enrolled20 locationsNCT06840834
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ETOP IBCSG Partners Foundation290 enrolled42 locationsNCT06284317
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Unresectable Pleural Mesothelioma
AstraZeneca825 enrolled178 locationsNCT06097728
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled94 locationsNCT07213674
Recruiting
Phase 3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
Hot Flashes
Astellas Pharma Global Development, Inc.540 enrolled117 locationsNCT06440967
Recruiting
Phase 3
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique129 enrolled40 locationsNCT06937905
Recruiting
Phase 2
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Stage III NSCLC
Intergroupe Francophone de Cancerologie Thoracique152 enrolled25 locationsNCT06656598
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc674 enrolled203 locationsNCT06757634
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199